Terms: = Ovarian cancer AND FUBP1, FBP, 8880, ENSG00000162613, FUBP AND Treatment
8 results:
1. Preparation and Performance of Chemotherapy Drug-Loaded Graphene Oxide-Based Nanosheets That Target ovarian cancer Cells via Folate Receptor Mediation.
Wang J; Han S; Zhang Z; Wang J; Zhang G
J Biomed Nanotechnol; 2021 May; 17(5):960-970. PubMed ID: 34082881
[TBL] [Abstract] [Full Text] [Related]
2. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
[TBL] [Abstract] [Full Text] [Related]
3. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract] [Full Text] [Related]
4. Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens.
Smans KA; Ingvarsson MB; Lindgren P; Canevari S; Walt H; Stigbrand T; Bäckström T; Millán JL
Int J Cancer; 1999 Oct; 83(2):270-7. PubMed ID: 10471538
[TBL] [Abstract] [Full Text] [Related]
5. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract] [Full Text] [Related]
6. Overexpression of folate binding protein in ovarian cancers.
Toffoli G; Cernigoi C; Russo A; Gallo A; Bagnoli M; Boiocchi M
Int J Cancer; 1997 Apr; 74(2):193-8. PubMed ID: 9133455
[TBL] [Abstract] [Full Text] [Related]
7. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract] [Full Text] [Related]
8. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo.
Bottero F; Tomassetti A; Canevari S; Miotti S; Ménard S; Colnaghi MI
Cancer Res; 1993 Dec; 53(23):5791-6. PubMed ID: 8242637
[TBL] [Abstract] [Full Text] [Related]
